Dashboard

Regeneron Pharmaceuticals, Inc.

REGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$68B

Price$656.0152w $483.07 – $812.27

Conviction4/ 5

Revenue (TTM)$14.9B

Revenue growth YoY+5.9%

P/E (trailing)15.3

Gross margin84.5%

Operating margin24.3%

Net margin29.6%

52w price change+33.7%

Next earningsJul 30, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 7
Ownership changeSEC
Form 4 insider ownership filing
Jul 6
Financial resultsSEC
Regeneron filed Form 8-K item 2.02 on results of operations and financial condition.
Jun 17
OtherSEC
Regeneron filed Form 8-K (item 5.07) disclosing results of matters submitted to security holder vote.
Jun 3
Trial initiationClinicalTrials.gov
Viz.ai trial NCT07118306 (COPD Exacerbation Follow Up) status updated to recruiting
May 15
Trial initiationClinicalTrials.gov
Phase 2 platform trial (NCT07058012) recruiting for cemiplimab monotherapy or + fianlimab in colorectal cancer with MRD post-surgery/chemotherapy
May 4
OtherSEC
SEC Form 4 insider ownership filing

Not financial advice — research and opinion only. Disclosures